

UPMC Hillman Cancer Center, Partnered with University of Pittsburgh Cancer Institute, and the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences presents:

2024 Review of the San Antonio Breast Cancer Symposium

Date: Friday, February 7, 2025

Time: 8:00 am to 2:00 pm

Location: The Assembly (Pittsburgh) and Microsoft TEAMS

Course Directors

Dhaval Mehta, MD
Clinical Assistant Professor,
University of Pittsburgh School of Medicine
Medical Oncologist, UPMC Hillman Cancer Center

Shannon Puhalla, MD
Clinical Assistant Professor,
University of Pittsburgh School of Medicine
Medical Oncologist, UPMC Hillman Cancer Center

Program Goal

This program is designed to discuss the content presented at the 2024 San Antonio Breast Cancer Symposium. Topics surrounding experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease will be highlighted.

Target Audience

Advanced practice providers, nurses, pharmacists, physicians, social workers, and other health care professionals who work with individuals diagnosed with breast cancer.

Course Objectives

- Apply cutting edge research in medical and surgical breast oncology into clinical practice
- Discuss advancements made in radiation oncology related to breast cancer
- Identify the current initiatives surrounding palliative and supportive care within breast cancer management
- Recall premalignant disease management with breast oncology
- Recognize efforts involved in breast cancer health maintenance, prevention, and survivorship
- Understand the mechanism of action for the most current pharmaceutical advancements

Accreditation and Credit Designation

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME): The University of Pittsburgh designates this live activity for a maximum of *4.25 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE): The maximum number of hours awarded for this Continuing Nursing Education activity is 4.25 contact hours.

Physician Assistant (AAPA): The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Pharmacy (CPE): This knowledge-based activity provides 4.25 contact hours of continuing pharmacy education credit.

Social Work (ASWB): As a Jointly Accredited Organization, the University of Pittsburgh is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 4.25 continuing education credits.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

We gratefully acknowledge support from the following exhibitors for this activity:

AbbVie, American Cancer Society, Amgen, AstraZeneca, Bayer Pharmaceuticals, Inc., BeiGene, Cancer Bridges, Daiichi Sankyo, Inc., Gilead Oncology, Guardant Health, Hologic, Lilly Oncology, Menarini Stemline Therapeutics, Merck, NeoGenomics, Novartis Oncology, Pfizer, Pittsburgh Hearts of Steel, UPMC Moving Through Cancer Program, and Young Adult Survivors United.

Faculty

Parul Barry, MD, FACRO

*Clinical Assistant Professor,
Department of Radiation Oncology
University of Pittsburgh School of Medicine
Radiation Oncologist
UPMC Hillman Cancer Center*

Michael Cowher, MD

*Associate Professor of Surgery,
University of Pittsburgh School of Medicine
Director, Breast Program
UPMC Jameson*

Julia Foldi, MD, PhD

*Assistant Professor of Medicine,
Division of Malignant Hematology and
Medical Oncology
University of Pittsburgh School of Medicine
Medical Oncologist
UPMC Hillman Cancer Center*

Kit Lu, MD

*Director, Clinical Trials Program
Associate Director,
UPMC Hillman Cancer Center, Central PA
Clinical Assistant Professor,
University of Pittsburgh School of Medicine*

Meaghan Marley, MD

*Breast Surgical Oncologist
UPMC Altoona
UPMC Magee-Womens Hospital*

Priya Rastogi, MD

*Professor, University of Pittsburgh School
of Medicine
Medical Oncologist
Magee-Womens Hospital*

Adam Brufsky, MD, PhD, FACP

*Professor of Medicine and Associate Chief, Division of Hematology Oncology,
University of Pittsburgh School of Medicine
Medical Director, Magee-Womens Cancer Program
Associate Director, Clinical Investigations, UPMC Hillman Cancer Center
Co-Director, Comprehensive Breast Cancer Center, UPMC Magee-Womens
Hospital*

Emilia Diego, MD

*Vice-Chair, Diversity and Inclusion; Associate Professor of Surgery,
University of Pittsburgh School of Medicine
Program Director, Breast Surgical Oncology Fellowship; Director, Pre-Menopausal
Breast Cancer Program,
UPMC Magee-Womens Hospital
Division Chief, Breast Surgery; Co-Director,
UPMC Hillman Cancer Center and Magee-Womens Hospital Breast Cancer
Program*

Charles Geyer, MD, FACP

*Interim Chief, Professor of Medicine
Division of Malignant Hematology
and Medical Oncology,
University of Pittsburgh School of
Medicine
Breast Medical Oncologist
UPMC Hillman Cancer Center*

Rahul Kumar, MD

*Clinical Assistant Professor,
Department of Radiation Oncology
University of Pittsburgh School of
Medicine
Radiation Oncologist
UPMC Hillman Cancer Center*

Kristin Lupinacci, DO, FACOS, FACS

*Assistant Professor of Surgery,
University of Pittsburgh School of
Medicine
Breast Surgical Oncologist
UPMC Magee-Womens Hospital*

Phuong Mai, MD, MS

*Associate Professor,
Obstetrics, Gynecology, and
Reproductive Sciences
UPMC Magee Center for Medical
Genetics and Genomics
UPMC Hillman Cancer Center*

Priscilla McAuliffe, MD, PhD, FACS

*Breast Surgical Oncologist,
UPMC Hillman Cancer Center
Assistant Professor of Surgery,
Division of Surgical Oncology
University of Pittsburgh School of
Medicine*

Steffi Oesterreich, PhD

*Professor, University of Pittsburgh
School of Medicine
Co-Director, Women's Cancer Research
Center
Magee-Womens Research Institute
Co-Leader, Cancer Biology Program
UPMC Hillman Cancer Center*

Faculty Disclosures

All individuals in a position to control the content of this education activity have disclosed all financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All the relevant financial relationships for the individuals listed below have been mitigated:

Parul Barry: ACRO, Beckwith Institute, Pittsburgh Foundation, Silverlon (Grant/Research Support); Elsevier Pathways (Consultant); Osler Board Review, ASTRO, ACRO, Onclive, Varian (Honorarium); ASTRO and ACRO (Travel expenses)
Adam Brufsky: Agendia, AstraZeneca (Grant/Research Support); AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, Puma (Consultant)
Charles Geyer: AstraZeneca, Daiichi Sankyo, Exact Sciences, and Genentech/Roche (Grant/Research Support)
Kit Lu: AstraZeneca, Daiichi Sankyo, Gilead, Merck, Stemline, and Seagen (CE Speaker's Bureau)
Priscilla McAuliffe: AstraZeneca (Consultant)
Dhaval Mehta: AstraZeneca, Curio Science, and Integra Connect (Consultant)
Shannon Puhalla: AstraZeneca and Novartis (Consultant)

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Agenda

7:30 am	Registration and Breakfast (Live Attendees) and TEAMS login (Virtual Attendees)	
8:00 am	Welcome	Dhaval Mehta, MD and Shannon Puhalla, MD
8:05 am	HER2 Positive Breast Cancer	Adam Brufsky, MD, PhD, FACP
8:35 am	Early Triple Negative Breast Cancer	Charles Geyer, MD, FACP
9:05 am	Break	
9:15 am	ER Positive Breast Cancer	Priya Rastogi, MD
9:45 am	Circulating Tumor DNA in Breast Cancer	Julia Foldi, MD, PhD
10:15 am	ER Positive Metastatic Breast Cancer	Kit Lu, MD
10:45 am	Keynote Address	Steffi Oesterreich, PhD
11:15 am	Lunch	
11:45 am	Metastatic Triple Negative Breast Cancer and PARP Inhibitors	Shannon Puhalla, MD
12:15 pm	Surgical Oncology Abstracts	Priscilla McAuliffe, MD, PhD, FACS Kristin Lupinacci, DO, FACOS, FACS Michael Cowher, MD Emilia Diego, MD Meaghan Marley, MD
12:45 pm	Radiation Oncology Abstracts	Parul Barry, MD, FACRO Rahul Kumar, MD
1:15 pm	Genetics and Genomics	Phuong Mai, MD, MS
1:45 pm	Wrap up and Q&A	
2:00 pm	Adjournment	